# reload+after+2024-01-20 16:47:34.605177
address1§3963 Maple Avenue
address2§Suite 350
city§Dallas
state§TX
zip§75219
country§United States
phone§972 499 3350
website§https://instilbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
fullTimeEmployees§192
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Bronson  Crouch', 'age': 50, 'title': 'Chairman & CEO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 672367, 'exercisedValue': 0, 'unexercisedValue': 250017}, {'maxAge': 1, 'name': 'Dr. Sandeep  Laumas M.D.', 'age': 54, 'title': 'CFO & Chief Business Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 489139, 'exercisedValue': 0, 'unexercisedValue': 437900}, {'maxAge': 1, 'name': 'Dr. Mark E. Dudley Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert  Hawkins MBBS, Ph.D.', 'title': 'Head of Research & Development', 'fiscalYear': 2022, 'totalPay': 218720, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.186
currency§USD
dateShortInterest§1702598400
forwardEps§-12.9
exchange§NCM
quoteType§EQUITY
shortName§Instil Bio, Inc.
longName§Instil Bio, Inc.
firstTradeDateEpochUtc§1616160600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f6e98ce3-ca96-34e6-a1c6-796bed2d60df
gmtOffSetMilliseconds§-18000000
targetHighPrice§100.0
targetLowPrice§40.0
targetMeanPrice§70.0
targetMedianPrice§70.0
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§2
quickRatio§13.622
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
